• 湿润烧伤膏联合康复新液防治放射性皮肤及黏膜损伤的疗效观察
  • Observation on the Clinical Efficacy of MEBO in Combination with Kangfuxin Solution in the Prevention and Treatment of Radioactive Skin and Mucosal Injuries
  • 卢衍萍,武 霞.湿润烧伤膏联合康复新液防治放射性皮肤及黏膜损伤的疗效观察[J].中国烧伤创疡杂志,2018,(3):197~204.
    DOI:
    中文关键词:  湿润烧伤膏  康复新液  宫颈癌  放射治疗  放射性皮肤损伤  放射性黏膜损伤  疗效
    英文关键词:MEBO  Kangfuxin solution  Cervical cancer  Radiotherapy  Skin radioactive injury  Mucosa radioactive injury  Efficacy
    基金项目:
    作者单位
    卢衍萍 临沂市第三人民医院肿瘤科 
    武 霞 临沂市第三人民医院肿瘤科 
    摘要点击次数: 1896
    全文下载次数: 2890
    中文摘要:
          【摘要】 目的 探讨湿润烧伤膏联合康复新液防治宫颈癌放射治疗致放射性皮肤及黏膜损伤的临床疗效。方法 将2014年10月—2017年10月临沂市第三人民医院肿瘤科收治的接受放射治疗的120例Ⅱ~Ⅳ期宫颈癌患者按照随机数表法随机分为观察组(60例) 与对照组(60例), 其中观察组患者于放射治疗后采用湿润烧伤膏联合康复新液护理会阴部, 对照组患者于放射治疗后采用生理盐水护理会阴部, 对比观察两组患者的皮肤及黏膜损伤情况、疼痛情况及中断治疗情况。结果 放射治疗30Gy、50Gy 及疗程结束后, 两组患者皮肤及黏膜损伤情况对比采用卡方检验, χ2值分别为47.442、77.538 及87.144, P均<0.01, 差异具有统计学意义; 两组患者皮肤及黏膜损伤出现时间对比采用u检验, u = 48.235, P<0.01, 差异具有统计学意义; 放射治疗30Gy、50Gy及疗程结束后, 两组患者局部疼痛情况对比采用卡方检验, χ2值分别为60.000、70.769 及72.000, P均<0.01, 差异具有统计学意义; 两组患者局部疼痛出现时间对比采用u检验, u=32.295, P<0.01, 差异具有统计学意义; 治疗过程中观察组无1 例患者中断治疗, 对照组有10例患者中断治疗, 中断时间为(12.80±2.60)d,两组对比采用u检验, u=38.134, P<0.01, 差异具有统计学意义。结论 湿润烧伤膏联合康复新液可有效防治宫颈癌放射治疗后放射性皮肤及黏膜损伤, 缓解局部疼痛, 避免因不良反应导致的中断治疗, 疗效显著, 具有较高的临床应用价值。
    英文摘要:
          【Abstract】 Objective To study the clinical efficacy of MEBO in combination with Kangfuxin solution in the prevention and treatment of radioactive skin and mucosal injuries resulting from radiotherapy for cervical cancer. Methods One hundred and twenty patients with cervical cancer of stage Ⅱ-Ⅳ, admitted to Oncology Department of The Third People’s Hospital of Linyi from October 2014 to October 2017 were randomly divided into an observation group (60 cases) and a control group (60 cases) according to the random number table. MEBO in combination with Kangfuxin solution was applied on perinea of patients in the observation group after radiotherapy while normal saline was used to rinse perinea of patients in the control group after radiotherapy. Skin and mucosal injuries, pain and treatment interruption were observed and compared between the two groups. Results At three respective time points of dosage 30Gy and 50Gy and the completion of radiotherapy, the Chi-square test was used for the comparison of skin and mucosal injuries of patients in the two groups and the results showed statistically significant difference (χ2=47.442, 77.538 and 87.144 respectively, all P<0.01); the u test was adopted for the occurrence time comparison of skin and mucosal injuries between the two groups and the results showed statistically significant difference (u=48.235, P<0.01). Also at the three respective time points, the local pain of patients in the two groups was compared with the Chi-square test and the results showed statistically significant difference (χ2=60.000, 70.769 and 72.000 respectively, P<0.01), and the u test was adopted for the occurrence time comparison of local pain and the difference was statistically significant (u=32.295, P<0.01). None of patients discontinued the treatment in the observation group while 10 patients interrupted the treatment in the control group with the interruption duration of (12.80±2.60) d, which was compared with the u test and the results showed statistically significant difference (u=38.134, P<0.01). Conclusion The therapy of MEBO in combination with Kangfuxin solution can effectively prevent the occurrence of radioactive skin and mucosal injuries and local pain caused by radiotherapy for cervical cancer, and avoid treatment interruption due to adverse reactions, deserving to be promoted in medical practice.